Brain+ begins early activity and brand building in the US
Brain+ begins early activity and brand building in the US The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing Brain+ has been selected and featured as a 2022 TMC-Denmark BioBridge Partner in the new Texas Medical Center (TMC) 2022 Biobridge e-book. TMC is the […]
First milestone met
Brain+ meets milestone with Rox Health (Roche Germany) Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch. Meeting this milestone unlocks access for Brain+ to additional expert resources in the Rox Health/Roche organization and triggers a minor milestone payment. The following milestones will be product launch […]
New Research report values Brain+
New research report values Brain+ at DKK 4.1 per share in the base case, and DKK 6.4 in the bull case. The research report concludes that “Brain+ is in a strong position to grow towards a market leadership position within Digital Therapeutics for dementia, based on a unique and differentiated product offering… …combined with a […]
Accelerated launch Q2 2023
Brain+ partners with German medical distributor Advances launch of its first CST dementia product in Germany to Q2 2023 Through Coopmed, Brain+ will be represented by experienced and local medical sales managers in Germany and begin to build the customer pipeline in preparation for the commercial launch of its first CST dementia product, […]
Brain+’ new product for dementia launching Q4 2022
Brain+’ new product for dementia launching Q4 2022 Digital “CST–Therapist Companion” is launching one year ahead of plan The Brain+ “CST-Therapist Companion” is a new digital product to deliver Cognitive Stimulation Therapy (CST), a globally recognized evidence-based non-pharmaceutical dementia therapy The Danish market for the Brain+ digital CST products, of which CST-Therapist […]
Growing interest in DTx from big pharma
Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other types of dementia and help relieve the growing burden of these conditions on patients, relatives, and societies. According to the […]
Growing interest in DTx from big pharma
Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other types of dementia and help relieve the growing burden of these conditions on patients, relatives, and societies. According to the […]
Dementia in Denmark – Is the healthcare system ready? (NO!)
[vc_row][vc_column][vc_single_image image=”9768″ img_size=”full” alignment=”center”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] Dementia in Denmark – Is the healthcare system ready? (NO!) [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]“Get started now!” – was the clear call to action for the healthcare system and politicians from Pia, who was diagnosed with Alzheimer’s at a young age and who is now in early retirement. Brain+ participated at Christiansborg (The Danish Parliament) […]
